NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Why the study?
Knowledge gaps and challenges remained in fully understanding the role of Lp(a) in CVD and CAVD, despite evidence that it is a causal mediator.
Design
Working group recommendations
Authors
Discussion
Loading...
Member takes
Implication
Await outcome trials before targeting Lp(a) in practice; leaves open broader insights into causality beyond binary results.**[[1]](https://x.
Key Points
- The aim is to address the role of lipoprotein(a) in cardiovascular disease and calcific aortic valve disease, including identifying challenges in research.
- Organized a working group by the National Heart, Lung, and Blood Institute to discuss lipoprotein(a) challenges.
- Identified specific recommendations for improving research and understanding of lipoprotein(a).
- Emphasized collaboration and resource sharing among research entities.
- Identified knowledge gaps in the understanding of lipoprotein(a) and its role in disease.
- Highlighted the need for standardized Lp(a) assays and better experimental models.
- Recommended concerted research efforts to improve diagnostic and therapeutic advancements for lipoprotein(a).
Cite This Study
Tsimikas et al. (2018) studied this question.